scholarly journals Comparative Effectiveness Analysis Of CD34+Selected, T-Cell Depleted (TCD) HLA-Matched Sibling Grafts On Allogeneic Hematopoietic Cell Transplantation For Patients With Acute Myeloid Leukemia (AML) In Complete Remission

2010 ◽  
Vol 16 (2) ◽  
pp. S268
Author(s):  
M.C. Pasquini ◽  
S. Devine ◽  
A. Mendizabal ◽  
L.R. Baden ◽  
J.R. Wingard ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
T Cell ◽  
Complete Remission ◽  
Comparative Effectiveness ◽  
Myeloid Leukemia ◽  
Hematopoietic Cell Transplantation ◽  
Effectiveness Analysis ◽  
Matched Sibling ◽  
Comparative Effectiveness Analysis ◽  
Acute Myeloid

scholarly journals Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission

2019 ◽  
Vol 3 (12) ◽  
pp. 1826-1836 ◽  
Author(s):  
Armin Rashidi ◽  
Mehdi Hamadani ◽  
Mei-Jie Zhang ◽  
Hai-Lin Wang ◽  
Hisham Abdel-Azim ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Complete Remission ◽  
Myeloid Leukemia ◽  
Calcineurin Inhibitor ◽  
Chronic Gvhd ◽  
Gvhd Prophylaxis ◽  
Matched Sibling ◽  
Conditioning Intensity ◽  
First Complete Remission ◽  
Acute Myeloid

Abstract HLA-haploidentical hematopoietic cell transplantation (Haplo-HCT) using posttransplantation cyclophosphamide (PT-Cy) has improved donor availability. However, a matched sibling donor (MSD) is still considered the optimal donor. Using the Center for International Blood and Marrow Transplant Research database, we compared outcomes after Haplo-HCT vs MSD in patients with acute myeloid leukemia (AML) in first complete remission (CR1). Data from 1205 adult CR1 AML patients (2008-2015) were analyzed. A total of 336 patients underwent PT-Cy–based Haplo-HCT and 869 underwent MSD using calcineurin inhibitor–based graft-versus-host disease (GVHD) prophylaxis. The Haplo-HCT group included more reduced-intensity conditioning (65% vs 30%) and bone marrow grafts (62% vs 7%), consistent with current practice. In multivariable analysis, Haplo-HCT and MSD groups were not different with regard to overall survival (P = .15), leukemia-free survival (P = .50), nonrelapse mortality (P = .16), relapse (P = .90), or grade II-IV acute GVHD (P = .98). However, the Haplo-HCT group had a significantly lower rate of chronic GVHD (hazard ratio, 0.38; 95% confidence interval, 0.30-0.48; P < .001). Results of subgroup analyses by conditioning intensity and graft source suggested that the reduced incidence of chronic GVHD in Haplo-HCT is not limited to a specific graft source or conditioning intensity. Center effect and minimal residual disease–donor type interaction were not predictors of outcome. Our results indicate a lower rate of chronic GVHD after PT-Cy–based Haplo-HCT vs MSD using calcineurin inhibitor–based GVHD prophylaxis, but similar other outcomes, in patients with AML in CR1. Haplo-HCT is a viable alternative to MSD in these patients.

Sign in / Sign up

Export Citation Format

Share Document